Tralokinumab is in development for the treatment of moderate to severe atopic dermatitis (AD) uncontrolled with currently available therapies in adult patients who are candidates for systematic therapy. AD is a chronic inflammatory skin disease that affects both children and adults and is characterised by redness, itchiness, and scaling of the skin. Some people only have small patches of dry skin, but others may experience widespread red, inflamed skin all over the body. Patients with moderate to severe AD could come across with sleep disturbances, anxiety, depression, and poor quality of life. Currently, the management of AD involves the removal or treatment of trigger factors that contribute to the development of the disease.
Tralokinumab is a human monoclonal antibody that binds and neutralises the effect of the protein interleukin 13 (IL-13), which plays a key role in triggering immune system responses in patients leading to AD. Tralokinumab is taken subcutaneously (SC), and trial evidence suggests it has been associated with improvements in disease symptoms. If licensed, tralokinumab will offer an additional treatment option for adults with moderate to severe AD who are candidates for systematic therapy, who may or may not use steroid cream previously.
Secukinumab as a subcutaneous injection is in clinical development for the treatment of enthesitis related arthritis (ERA) and juvenile psoriatic arthritis (JPsA). These conditions belong to a group of arthritis conditions of unknown cause known as juvenile idiopathic arthritis which affect children. JPsA patients have arthritis and psoriasis, an inflammatory skin disease and ERA patients have arthritis and enthesitis, inflammation of the ligaments and tendons. These conditions are the result of the immune system mistakenly attacking the body’s own cells at the joints and the skin or tendons, causing swelling, pain and reduced mobility.